STAT July 24, 2024
Viking Therapeutics plans to move its injectable obesity treatment into a Phase 3 study faster than expected, bringing the biotech closer to joining the highly competitive GLP-1 drug market.
The San Diego-based biotech previously said it was anticipating to start a Phase 2b trial of the therapy, VK2735, after getting positive results from a Phase 2 study. But after receiving feedback from regulators, the company now plans to advance directly into a Phase 3 trial, the...
Today's Sponsors
Today's Sponsor